Business Context and Reporting Period
Pulse Biosciences, Inc. (PLSE) filed a Form 8-K on July 29, 2026, reporting a significant milestone in its clinical development program. The Company is a Delaware corporation headquartered in Hayward, California, focused on cardiac catheter systems.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the surpassing of the enrollment midpoint for the NANOPULSE-AF clinical study. Key details include:
- Study Status: Enrollment midpoint achieved as of July 29, 2026.
- Study Type: Prospective, multicenter, pivotal clinical investigation.
- Product: nPulse Cardiac Catheter System.
- Indication: Treatment of recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation.
- Timeline: Study commenced in April 2026.
- Scope: Up to 30 sites, including international locations.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the inherent uncertainties of clinical trials. The report focuses solely on the operational progress of the NANOPULSE-AF study.
Investor Verification Checklist
- Verify the total planned enrollment number for the NANOPULSE-AF study to assess the remaining timeline to completion.
- Review the attached Press Release (Exhibit 99.1) for specific details on patient demographics and site activation rates.
- Monitor upcoming filings for data readouts or secondary endpoints from the pivotal study.
- Check the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.